bioRxiv Science⌕ Search

Biology subjects

HERAUD, C.

Publications and source records attributed to HERAUD, C..

2 recordsLinked to original sources

Mass Spectrometry-Based Profiling of Deuterium-Labeled Sex Steroids Enables Non-Invasive Mapping of Steroid Dynamics in Intact Mice

Background and purpose Sex steroids play central roles in endocrine regulation and are major therapeutic targets in multiple hormone-dependent disorders. However, understanding the tissue-specific pharmacokinetics, distribution and metabolism of these hormones remains challenging in vivo, as most experimental approaches rely on surgical castration, which profoundly disrupts endocrine homeostasis and limits translational relevance for pharmacological studies. We therefore developed a strategy enabling quantitative analysis of steroid dynamics in physiologically intact animals. Experimental approach We established a mass spectrometry-based platform combining systemic administration of deuterium-labelled sex steroids (E2-d4, Testo-d3 and DHEA-d5) with high-sensitivity GC-MS/MS to simultaneously quantify exogenous tracers, endogenous steroids and their metabolites in serum and multiple tissues of intact, non-castrated mice. Key results This approach enabled temporally resolved tracking of steroid uptake, distribution and biotransformation in gonadally intact animals, providing a baseline that is closer to native physiology than in castration-based paradigms. In male and female mice, the method revealed organ-specific accumulation patterns of the metabolites of injected deuterium-labelled sex steroids, including E2-to-E1 conversion in ovary and hippocampus and Testo-to-DHT conversion in prostate and seminal vesicle, that are consistent with the distribution of steroidogenic enzymes in these tissues. Conclusion and implications This methodology provides a physiologically relevant framework for investigating steroid pharmacokinetics and pharmacodynamics in vivo, in which local versus systemic contributions can be dissected in future perturbation studies. By enabling quantitative mapping of steroid metabolism across tissues, it offers a powerful tool for endocrine pharmacology and for the development and evaluation of therapies targeting steroid pathways. It may, thus, facilitate mechanistic studies and preclinical evaluation of anti-androgen therapies, steroidogenesis inhibitors, and other treatments used in hormone-dependent cancers.

biochemistry↗

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer, a novel cancer-relevant paralog interplay

Endometrial cancer is one of the main gynecological malignancies worldwide, with an estimated 320, 000 new cases annually. Several studies highlight ARHGAP35 as a significantly mutated gene in these tumors. It encodes for the protein p190RhoGAP-A (p190A), which is a major regulator of the small GTPase family of proteins. ARHGAP5 is a paralog of ARHGAP35 that encodes the protein p190RhoGAP-B (p190B). By analyzing human endometrial cancer samples, we found a co-occurrence of mutations in ARHGAP35 and ARHGAP5 genes and we reported that both are less expressed at the mRNA level in tumoral samples compared to healthy tissues. We were interested in understanding the impact of p190A/B under-expression in endometrial cancer and the relationship between the two paralogs. To do so, we have used CRISPR/Cas9 technology to generate HEC-1-A knockout cells for p190A and p190B. We showed that removal of each paralog led to a similar actin remodeling phenotype with the formation of Cross-Linked Actin Networks (CLANs), dependent on the Rho/ROCK pathway. Moreover, proteomic analysis of p190A and p190B knockout cells highlighted similar affected cell functions. Finally, our study demonstrates a synthetic lethality between p190A and p190B where removal of both paralogs is deleterious in endometrial cancer cells, unveiling a potential actionable vulnerability.

cancer biology↗